AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of the combination of the two
drugs cediranib and temsirolimus and the highest doses of these two drugs that can be given
in combination to people safely. Cediranib is a drug that may stop blood supply to the tumor
and therefore help keep cancer cells from growing. Temsirolimus is a drug that may stop
cancer cells from growing. These drugs have been used in other research studies in ovarian
and kidney cancer and these studies suggest that these drugs may help to keep cancer from
growing in this research study.
Phase:
Phase 1
Details
Lead Sponsor:
Susana M. Campos, MD
Collaborators:
AstraZeneca Beth Israel Deaconess Medical Center Massachusetts General Hospital National Comprehensive Cancer Network Wyeth is now a wholly owned subsidiary of Pfizer